Occurrence of cardiotoxicity in breast cancer patients treated with doxorubicin hydrochloride chemotherapy and influence factors
Objective To determine the occurrence of cardiotoxicity and risk factors in female breast cancer patients after application of doxorubicin hydrochloride chemotherapy.Methods Totally 130 clinical data of female breast cancer patients who received doxorubicin chemotherapy from 2020 to 2022 in a tertiary hospital were selected and divided into a cardiotoxicity group(n=28)and a non-cardiotoxicity group(n=102)according to the occurrence of cardiotoxicity.General data of patients such as age,tumor stage,pathological grading,history of previous diseases,combined treatment regimen,combined medication,and radiotherapy,etc.,were collected and the risk factors for the occurrence of cardiotoxicity were determined by Logistic regression analysis.Results Cardiotoxicity occurred in 28(21.54％)of the 130 breast cancer patients receiving doxorubicin chemotherapy.Age≥60 years,history of hypertension,cumulative dose≥160 mg and combination radiotherapy were independent risk factors for cardiotoxicity.Conclusion Age,hypertension,cumulative dose and combined radiotherapy are the risk factors for cardiotoxicity in breast cancer patients receiving doxorubicin chemotherapy.We should pay close attention to the clinical use of drugs in senior patients receiving combined radiotherapy,and monitor cardiac function indexes.Meanwhile,the dosage of chemotherapy should be reduced or combined with cardioprotective agent dexrazoxane to prevent or reduce the occurrence of cardiotoxicity.
NETL
NSTL
万方数据
